ISRG earnings analysis
What we found in ISRG's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Intuitive delivered a strong Q2, with revenue up 19% year over year to $2.892 billion, gross margin up 150 basis points to 67.8%, and operating income up 31% to $972.0 million. Growth was broad-based across instruments and accessories, systems, service, U.S., and OUS revenue, with procedure growth and da Vinci 5 adoption driving results. Liquidity remains substantial at $8.63 billion of cash, cash equivalents, and investments, although it declined $0.41 billion from year-end following $1.44 billion of six-month share repurchases, a $528 million acquisition, and inventory investment. The filing does not provide reported EPS in the extracted text or new numeric financial guidance; key offsets are decelerating procedure growth, China demand/policy pressure, and tariff uncertainty.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth remained strong
- Q2 revenue increased 19% year over year to $2.892 billion from $2.440 billion. This also represents a $122.3 million, or roughly 4.4%, increase from the $2.770 billion reported in Q1 2026.
- Margins expanded sharply
- Gross margin expanded 150 basis points year over year to 67.8% from 66.3%, while operating income rose 31% to $972.0 million from $743.0 million. The resulting operating margin was 33.6%, up from 30.5% a year earlier and 30.9% in Q1 2026.
- Procedure-led recurring revenue growth
- Instruments and accessories revenue rose 18% to $1.735 billion, supported by 15% growth in da Vinci procedures to approximately 889,000 and 36% growth in Ion procedures to approximately 47,900.
- Da Vinci 5 supported system demand
- Da Vinci placements increased 18% to 468 systems, including 246 da Vinci 5 systems versus 180 a year ago. The installed base reached approximately 11,710 systems, up 12% from approximately 10,488.
- Operating cash flow accelerated
- Six-month operating cash flow increased to $1.973 billion from $1.297 billion. Capital expenditures were $216 million, equal to about 11% of operating cash flow, implying strong internally funded investment capacity.
- International adoption remained a growth driver
- International momentum remained robust: OUS procedures increased 20% to approximately 337,000 and OUS revenue rose 18% to $959.1 million. Management cited particular procedure strength in India, Italy, and the United Kingdom.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Updated risk: remanufactured instruments and service
- The sole formal risk-factor update states that third parties may offer remanufactured or unauthorized instruments and accessories and unauthorized system service. This is material because instruments and accessories generated $1.735 billion of Q2 revenue, and lower-priced alternatives could reduce revenue while creating patient-safety and reputational exposure.
- Tariff benefit may be nonrecurring
- Tariffs and other trade measures added $20.8 million to Q2 cost of revenue, while $35.9 million of prior IEEPA-tariff refunds reduced cost of revenue. The refund is a favorable but uncertain gain contingency, and future tariff rates or trade barriers could reverse the benefit.
- China competition and policy pressure
- China demand weakened relative to management expectations: the company placed 169 da Vinci systems under the original 2023 quota and 3 under special approval as of June 30, 2026, while citing domestic competition, tender delays, and national pricing constraints. China’s unified robotic-surgery pricing framework is to be implemented by all provinces in upcoming quarters.
- Inventory build increased working-capital use
- Working-capital investment consumed cash: inventory, including transfers to PP&E, increased $515 million in the first half, accounts receivable increased $50 million, and prepaids/other assets increased $179 million. These uses contributed to $870 million of cash consumption from operating asset and liability changes.
- Procedure growth decelerated
- Da Vinci procedure growth decelerated to 15% in Q2 2026 from 17% in Q2 2025; U.S. growth slowed to 12% from 14% and OUS growth to 20% from 23%. Management attributed part of the U.S. impact to expiration of enhanced ACA premium subsidies, while U.S. bariatric procedures declined by a high-single-digit percentage.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 67.8%
- Operating margin
- 33.6%
- Segment
- Instruments and accessories revenue: $1.735 billion, up 18% year over year from $1.474 billion.
- Segment
- Systems revenue: $685.0 million, up 19% year over year from $574.7 million.
- Segment
- Service revenue: $472.4 million, up 21% year over year from $391.2 million.
- Segment
- U.S. revenue: $1.933 billion, up 19% year over year from $1.629 billion.
- Segment
- OUS revenue: $959.1 million, up 18% year over year from $810.6 million.
What they said about what is next.
The 10-Q contains no new explicit numeric revenue or EPS guidance. Management says customers are expected to remain cautious on capital spending and expects R&D expense and depreciation expense to increase through the remainder of 2026; quantitative outlook is deferred to the earnings release/call.
The filing reads better than the one before it.
What came before.
- 10-Q · April 22, 2026
- Intuitive Surgical reported Q1 2026 revenue of $2,770.8 million, up $517.4 million (23.0%) versus Q1 2025 but down $99.2 million (3.5%) versus the prior quarter. Gross profit was $1,830.5 million (≈66.1% margin) and…
- 10-K · February 3, 2026
- Intuitive Surgical’s 10-K emphasizes continued commercialization of next-generation products (notably the da Vinci 5) and a comprehensive ecosystem of systems, instruments, and digital offerings. The company delivered…
- 10-Q · April 23, 2025
- Intuitive reported a strong quarter: revenue of $2,253.4M (+19.2% YoY vs $1,890.6M) and diluted EPS of $1.92 (vs $1.51 YoY), with operating cash flow of $581.6M and free cash flow of $465.0M. Gross margin was 64.7% and…
- 10-Q · April 19, 2024
- Intuitive reported Q1 revenue of $1,890.6 million (up $194.4M, +11.5% vs Q1 2023) and GAAP diluted EPS of $1.51 (vs $1.00). Gross profit rose to $1,245.4 million (65.9% margin) and operating income was $469.4 million…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ISRG makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever